TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34370331

Group type: EXPERIMENTAL
Intervention: Global Postural Reeducation (GPR)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control Group (CG) - no treatment
Number of subjects: 80
Study: 32659162

Group type: EXPERIMENTAL
Intervention: Compression stockings
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no compression stockings)
Number of subjects: 60
Study: 36168148

Group type: EXPERIMENTAL
Intervention: Riluzole oral film (ROF) 50 mg
Number of subjects: 41

Group type: COMPARATOR
Intervention: Riluzole tablets 50 mg
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Riluzole oral film (ROF) 50 mg with food
Number of subjects: 41
Study: 34688917

Group type: EXPERIMENTAL
Intervention: Pioglitazone (PPAR-γ agonist) adjunctive to cognitive-behavioral therapy (CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 0
Study: 34628066

Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM) therapy using a 670-nm light-emitting eye patch, applied for 90 seconds twice daily for 4 months.
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo using an identical device emitting broad-spectrum white light at low power, applied for 90 seconds twice daily for 4 months.
Number of subjects: 135
Study: 33394894

Group type: EXPERIMENTAL
Intervention: Linear Programming (LP)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Undulating Programming (UP)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Reverse Programming (RP)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Constant Programming (CP)
Number of subjects: 43
Study: 33095939

Group type: EXPERIMENTAL
Intervention: Pomegranate fruit extract (PFE) 1000 mg once daily for twelve months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 32050648

Group type: EXPERIMENTAL
Intervention: HIIT (10 sets of 6 s all‐out cycling interspersed with 9 s of rest)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: MICT (30 min cycling at 50%‐60% of peak oxygen consumption, V̇O2peak)
Number of subjects: 43

Group type: COMPARATOR
Intervention: No-exercise controls (CON)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: HIIT
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: MICT
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: HIIT and MICT
Number of subjects: 43
Study: 33921792

Group type: EXPERIMENTAL
Intervention: Fruit consumption
Number of subjects: 36496

Group type: EXPERIMENTAL
Intervention: Light levels of physical activity
Number of subjects: 36496

Group type: EXPERIMENTAL
Intervention: Whole milk consumption
Number of subjects: 36496
Study: 35951068

Group type: EXPERIMENTAL
Intervention: Thymosin α1 plus blood purification (BP) therapy
Number of subjects: 86

Group type: COMPARATOR
Intervention: Blood purification (BP) treatment only
Number of subjects: 86
Study: 34629245

Group type: EXPERIMENTAL
Intervention: 2800 IU of vitamin D3 per day
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 36415299

Group type: EXPERIMENTAL
Intervention: Self-management education program based on 5A model in five sessions during two months
Number of subjects: 54
Study: 32871870

Group type: EXPERIMENTAL
Intervention: PPI (Omeprazole; 40 mg twice daily)
Number of subjects: 12
Study: 36141796

Group type: EXPERIMENTAL
Intervention: RDIR (computerized intensive remediation strategy)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: RDOR (ordinary remediation strategy)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (Normal readers)
Number of subjects: 32
Study: 32303499

Group type: EXPERIMENTAL
Intervention: Monthly ranibizumab 0.3 mg every 4 weeks
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: TREX (treat-and-extend ranibizumab without laser)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: GILA (treat-and-extend ranibizumab with laser)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: All cohorts in the third year
Number of subjects: 150
Study: 32372585

Group type: EXPERIMENTAL
Intervention: Tailored counselling by a preventive nurse (telephone then mail)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Control group (no tailored counselling)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Nurse's interventions (post-intervention analysis)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Sociological analysis of families
Number of subjects: 304
Study: 35869988

Group type: EXPERIMENTAL
Intervention: Nicotine pouches (NPs) with 1.5 mg nicotine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nicotine pouches (NPs) with 2 mg nicotine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nicotine pouches (NPs) with 3.5 mg nicotine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nicotine pouches (NPs) with 8 mg nicotine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Own brand cigarettes (OBC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moist smokeless tobacco (OBMST)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nicotine pouches (NPs)
Number of subjects: 0
Study: 33006445

Group type: EXPERIMENTAL
Intervention: IV peramivir
Number of subjects: 179

Group type: COMPARATOR
Intervention: Oral oseltamivir
Number of subjects: 179
Study: 34969409

Group type: EXPERIMENTAL
Intervention: Humanized nursing care
Number of subjects: 50

Group type: COMPARATOR
Intervention: Routine nursing care
Number of subjects: 50
Study: 33248605

Group type: EXPERIMENTAL
Intervention: Vitamin D3 at 5,520 IU/kg (DD)
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Vitamin D3 at 2,760 IU/kg plus 25OHD at 2,760 IU (25D)
Number of subjects: 390

Group type: COMPARATOR
Intervention: Vitamin D3 at 2,760 IU/kg (D)
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: 25OHD
Number of subjects: 390
Study: 36184248

Group type: EXPERIMENTAL
Intervention: NRS-2002 scores by researchers
Number of subjects: 0

Group type: COMPARATOR
Intervention: NRS-2002 scores by department nurses
Number of subjects: 0
Study: 33719093

Group type: EXPERIMENTAL
Intervention: NeuroN-QI intervention (four 2-hour skin-to-skin contact sessions/week with 15-minute auditory stimulation, followed by a 1-hour quiet period)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard care (four skin-to-skin contacts per week)
Number of subjects: 24
Study: 32386940

Group type: EXPERIMENTAL
Intervention: Benson relaxation + routine care
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation + routine care
Number of subjects: 93

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 93
Study: 33760089

Group type: EXPERIMENTAL
Intervention: Behaviorally designed gamification intervention with a social support partner (12-week duration)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Control group received feedback from the wearable device only
Number of subjects: 232

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 232
Study: 32130757

Group type: EXPERIMENTAL
Intervention: Behavioral symptom abstinence plus meaningful reduction in EDE global scores
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Behavioral abstinence alone
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Higher EOT EDE global scores
Number of subjects: 110
Study: 35421999

Group type: EXPERIMENTAL
Intervention: navigation services
Number of subjects: 670

Group type: COMPARATOR
Intervention: electronic brochure
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: critical dialog or brief counseling
Number of subjects: 670
Study: 34887491

Group type: EXPERIMENTAL
Intervention: Voice-assisted AI coaching (MyCoach)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Autonomous AI coaching (SmartText)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (health information)
Number of subjects: 42
Study: 36107571

Group type: EXPERIMENTAL
Intervention: Artemether emulsion (1%)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Emulsion base
Number of subjects: 60
Study: 33130059

Group type: EXPERIMENTAL
Intervention: Vancomycin solution (5 mg/mL) soaking for 30 minutes
Number of subjects: 2

Group type: COMPARATOR
Intervention: Normal saline soaking for 30 minutes
Number of subjects: 2
Study: 36104122

Group type: EXPERIMENTAL
Intervention: SHAW educational programme plus access to the dayzz app for up to 9 months
Number of subjects: 1355

Group type: COMPARATOR
Intervention: Control group (received intervention at month 10)
Number of subjects: 1355
Study: 34352719

Group type: EXPERIMENTAL
Intervention: Two-session transition intervention led by registered nurses
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Two-session transition intervention
Number of subjects: 57

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 57
Study: 32379010

Group type: EXPERIMENTAL
Intervention: 14-week HIIT intervention (3 sessions/week)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 33176392

Group type: EXPERIMENTAL
Intervention: High-dose oxytocin
Number of subjects: 1008

Group type: COMPARATOR
Intervention: Low-dose oxytocin
Number of subjects: 1008
Study: 32249707

Group type: EXPERIMENTAL
Intervention: Recall of a positive memory
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Imagine a future positive event
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Recall of a negative memory
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Imagine a future negative event
Number of subjects: 342
Study: 35438091

Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (PUFAs) and phytosterol ester (PSE) co-supplementation
Number of subjects: 31
Study: 33845783

Group type: EXPERIMENTAL
Intervention: C2C6AR (the ratio of the angle between a line passing through the bottom of the second cervical vertebra and a line passing through the bottom of the sixth cervical vertebra in the extension position and the one in the neutral position)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Modified Mallampati test (MMT)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Hyomental distance (HMD)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Hyomental distance ratio (HMDR)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: C2C6AR
Number of subjects: 270
Study: 32217917

Group type: EXPERIMENTAL
Intervention: Midurethral sling (MUS)
Number of subjects: 17953
Study: 33597005

Group type: EXPERIMENTAL
Intervention: Novel diabetic therapeutic footwear (n = 160)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Own footwear (n = 160)
Number of subjects: 320
Study: 35732845

Group type: EXPERIMENTAL
Intervention: 4 oz prunes daily plus docusate sodium 100 g twice daily
Number of subjects: 77

Group type: COMPARATOR
Intervention: Docusate alone
Number of subjects: 77
Study: 33971153

Group type: EXPERIMENTAL
Intervention: Sonelokimab
Number of subjects: 310

Group type: COMPARATOR
Intervention: Secukinumab
Number of subjects: 310
Study: 32771424

Group type: EXPERIMENTAL
Intervention: LSG with antral resection (Group A)
Number of subjects: 279

Group type: COMPARATOR
Intervention: LSG with antral preservation (Group B)
Number of subjects: 279
Study: 35662148

Group type: EXPERIMENTAL
Intervention: School-based universal depression screening
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard symptom-based depression recognition
Number of subjects: 0
Study: 34006912

Group type: EXPERIMENTAL
Intervention: Hydration protocol (HP)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control protocol (CP)
Number of subjects: 28
Study: 32807539

Group type: EXPERIMENTAL
Intervention: Teaching intervention combining lay language, simplified handouts, provision of an unmarked dosing syringe, and teach-back to confirm correct dosing.
Number of subjects: 149

Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Teaching intervention.
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Teaching intervention (adjusted for health literacy and language).
Number of subjects: 149
Study: 36134918

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 3503

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3503
Study: 34526079

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (AC)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham acupuncture (SAC)
Number of subjects: 120
Study: 32669375

Group type: EXPERIMENTAL
Intervention: Ganetespib (200 mg/m2, days 1 and 15) with pemetrexed (500 mg/m2, day 1) and cisplatin (75 mg/m2, day 1) or carboplatin (AUC 5, day 1)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Ganetespib at MTD (200 mg/m2)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Ganetespib
Number of subjects: 27
Study: 34971646

Group type: EXPERIMENTAL
Intervention: Peanut allergen powder-dnfp (PTAH)
Number of subjects: 944

Group type: EXPERIMENTAL
Intervention: Peanut allergen powder-dnfp (PTAH) during updosing
Number of subjects: 944

Group type: EXPERIMENTAL
Intervention: Peanut allergen powder-dnfp (PTAH) during 300 mg maintenance
Number of subjects: 944
Study: 33440019

Group type: EXPERIMENTAL
Intervention: Propofol total intravenous anaesthesia
Number of subjects: 146

Group type: COMPARATOR
Intervention: Volatile-based maintenance anaesthesia
Number of subjects: 146
Study: 35042289

Group type: EXPERIMENTAL
Intervention: Radiomics nomogram model
Number of subjects: 114

Group type: COMPARATOR
Intervention: Radiomics model (12 optimal radiomics features)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Clinical relevant factors model (residual disease, neutrophil count, carbohydrate antigen 199)
Number of subjects: 114
Study: 32654042

Group type: EXPERIMENTAL
Intervention: Post-surgical logopedic rehabilitative training (Group A)
Number of subjects: 260

Group type: COMPARATOR
Intervention: No post-surgical treatment (Group B)
Number of subjects: 260
Study: 35928080

Group type: EXPERIMENTAL
Intervention: Fallopian Tube Sperm Perfusion (FSP)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard IUI (sIUI)
Number of subjects: 160
Study: 32214138

Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (less favorable treatment response)
Number of subjects: 66
Study: 33509804

Group type: EXPERIMENTAL
Intervention: 500 mg metformin
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 1,500 mg metformin
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Metformin (both dosages)
Number of subjects: 34
Study: 32320773

Group type: EXPERIMENTAL
Intervention: Curettage and imiquimod cream
Number of subjects: 145

Group type: COMPARATOR
Intervention: Surgical excision
Number of subjects: 145
Study: 33555670

Group type: EXPERIMENTAL
Intervention: Crossfit® (CF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LesMills® (LM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Traditional resistance (TRAD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 0
Study: 33280441

Group type: EXPERIMENTAL
Intervention: Astragalus membranaceus polysaccharide (APS) treatment
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (saline injection)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Infected group (goslings inoculated with goose parvovirus)
Number of subjects: 90
Study: 35975697

Group type: EXPERIMENTAL
Intervention: Goal-Based Outcome (GBO) tool
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 32700919

Group type: EXPERIMENTAL
Intervention: Indigenously adapted cognitive‐behavioral therapy for excessive smartphone use (IACBT‐ESU)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Brief educational data alone (Control)
Number of subjects: 62
Study: 36251032

Group type: EXPERIMENTAL
Intervention: Generic A
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Generic B
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Generic C
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Generic D
Number of subjects: 48

Group type: COMPARATOR
Intervention: L-asparaginase Medac (historical control)
Number of subjects: 48
Study: 32213316

Group type: EXPERIMENTAL
Intervention: Colistin (9 million units loading dose, followed by 4.5 MU twice daily maintenance dose)
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Colistin exposure
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: SOFA score at baseline
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Acinetobacter or Pseudomonas as index pathogen
Number of subjects: 406
Study: 34086087

Group type: EXPERIMENTAL
Intervention: Primary resection anastomosis (PRA)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Hartmann's procedure (HP)
Number of subjects: 78
Study: 32811480

Group type: EXPERIMENTAL
Intervention: eHealth intervention with personalized data integration from primary care EHR
Number of subjects: 934

Group type: EXPERIMENTAL
Intervention: eHealth intervention
Number of subjects: 934
Study: 35132659

Group type: EXPERIMENTAL
Intervention: CVVH
Number of subjects: 103

Group type: COMPARATOR
Intervention: non-CVVH
Number of subjects: 103
Study: 34582552

Group type: EXPERIMENTAL
Intervention: 1 cup of coffee (1C)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 3 cups of coffee (3C)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 1 cup of coffee + 2 CBPCC twice daily (PC)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 21
Study: 33484509

Group type: EXPERIMENTAL
Intervention: Physiotherapy with manual therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Physiotherapy alone
Number of subjects: 60
Study: 32304216

Group type: EXPERIMENTAL
Intervention: Remote monitoring care (RC)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 600
Study: 34346946

Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer cement sealant (Clinpro XT Varnish; 3M ESPE)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Topical fluoride varnish application (Duraphat; Colgate)
Number of subjects: 27
Study: 33982280

Group type: EXPERIMENTAL
Intervention: STAR intervention (family‐tailored education and problem‐solving behavioral intervention)
Number of subjects: 200

Group type: COMPARATOR
Intervention: EO intervention (education only)
Number of subjects: 200
Study: 35596932

Group type: EXPERIMENTAL
Intervention: Esketamine (ESK)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33682440

Group type: EXPERIMENTAL
Intervention: Ischemic stroke
Number of subjects: 4832

Group type: COMPARATOR
Intervention: Transient ischemic attack (TIA)
Number of subjects: 4832

Group type: EXPERIMENTAL
Intervention: Reclassified ischemic stroke
Number of subjects: 4832
Study: 32301894

Group type: EXPERIMENTAL
Intervention: TKDT granule (once per day for 24 weeks)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo (once per day for 24 weeks)
Number of subjects: 104
Study: 35448996

Group type: EXPERIMENTAL
Intervention: Practice change intervention (multi-strategy intervention over 7 months)
Number of subjects: 5694
Study: 33837095

Group type: EXPERIMENTAL
Intervention: ePROMs plus graphical displays of ePROM results to treating clinicians in consultations
Number of subjects: 0

Group type: COMPARATOR
Intervention: ePROMs without graphical display of ePROM results
Number of subjects: 0
Study: 32858717

Group type: EXPERIMENTAL
Intervention: Massage (daily 30-minute massage for 7 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (daily 30-minute restriction of nonessential caregiving for 7 days)
Number of subjects: 60
Study: 35488477

Group type: EXPERIMENTAL
Intervention: Guided Bone Regeneration (GBR)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Socket Seal (SS)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (unassisted socket healing)
Number of subjects: 14
Study: 34936740

Group type: EXPERIMENTAL
Intervention: Multicomponent diagnostic strategy (on-site molecular testing, guided restructuring of clinic workflows, monthly feedback of quality metrics)
Number of subjects: 10644

Group type: EXPERIMENTAL
Intervention: Multicomponent diagnostic strategy
Number of subjects: 10644

Group type: COMPARATOR
Intervention: Routine care (on-site sputum-smear microscopy and referral-based molecular testing)
Number of subjects: 10644
Study: 34474649

Group type: EXPERIMENTAL
Intervention: Escalation to first biologic
Number of subjects: 100

Group type: COMPARATOR
Intervention: Escalation in csDMARDs
Number of subjects: 100
Study: 32120028

Group type: EXPERIMENTAL
Intervention: Liothyronine (L-T3) 75 mcg total daily dose (TDD)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Liothyronine (L-T3)
Number of subjects: 15
Study: 33881368

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation
Number of subjects: 0
Study: 36053820

Group type: EXPERIMENTAL
Intervention: iGlarLixi
Number of subjects: 887

Group type: COMPARATOR
Intervention: BIAsp 30
Number of subjects: 887
Study: 34959798

Group type: EXPERIMENTAL
Intervention: Glucose beverage (125 mL semi-skimmed milk and 50 g glucose)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Intermittent sucrose beverage (125 mL semi-skimmed milk and 50 g sucrose)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Sucrose beverage (125 mL semi-skimmed milk and 50 g sucrose)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Isomaltulose beverage (125 mL semi-skimmed milk and 50 g isomaltulose)
Number of subjects: 11
Study: 36304565

Group type: EXPERIMENTAL
Intervention: CYP2D6 genotype treatment (G)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment (S)
Number of subjects: 0
Study: 32662840

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy at a power of 2 J/cm2 with a total of 4-6 J energy over each implant
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy
Number of subjects: 30
Study: 34937512

Group type: EXPERIMENTAL
Intervention: Recombinant corifollitropin alfa combined with highly purified urinary gonadotropin
Number of subjects: 51

Group type: COMPARATOR
Intervention: Recombinant follitropin/lutropin alfa within the protocol of applying gonadotropin-releasing hormone antagonists
Number of subjects: 51
Study: 35007129

Group type: EXPERIMENTAL
Intervention: LSVT‐1701, 6 mg/kg single dose
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: LSVT‐1701, 1.5 mg/kg twice daily for 4 days
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: LSVT‐1701, 3 mg/kg twice daily for 4 days
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: LSVT‐1701, 4.5 mg/kg twice daily for 4 days
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32